Home
  • Donate money to KEI
  • Listserves
  • Main Areas of Work
  • Events
  • Publications
  • Blogs
  • About KEI

Knowledge Ecology International

Attending and mending the knowledge ecosystem

Navigation

  • Site Map
  • Recent posts
  • Feed aggregator
  • Polls
  • Groups

Round II of the Paris Accord took place in Paris on October 23 and 24, 2009.

Book navigation

  • Right to Read for Persons with Reading Disabilities
  • About KEI
  • Access to Medical Technologies
  • Berne Convention Appendix Regarding Special Provisions Regarding Developing Countries
  • Competition Policy
  • Data points on prices of medical technologies
  • Databases
  • Enforcement and Remedies to Infringement
  • Events
  • General Access to Knowledge Issues
  • Government Funded Inventions
  • Knowledge Governance Fora
  • Main Areas of Work
  • Medical diseases, conditions and technologies
  • Nuclear Proliferation
  • Patent Policy
  • Prizes to stimulate innovation
  • Publications and Research Notes
  • Test Data
  • Timelines
  • Transparency

User login

What is OpenID?
  • Log in using OpenID
  • Cancel OpenID login
  • Create new account
  • Request new password
Home

Myozyme

Notes and data points for prices of orphan products

Submitted by James Love on 3. August 2010 - 13:50
  • Myozyme
  • Medical Technologies

February 22, 2010., Matthew Herper, "The World's Most Expensive Drugs," Forbes.

Genzyme's web page on the cost of treatment.

Some data points on Fabrazyme prices.

2004 prices for Replagal

  • Add new comment
  • Read more
Syndicate content

Support KEI

WASHINGTON 1621 Connecticut Ave. NW, Suite 500, Washington, DC 20009 /TEL: +1.202.332.2670 · FAX +1.202.332.2673 GENEVE 1 Route des Morillons, CP 2100, 1211 Genève 2, Switzerland TEL: +41.22.791.6727
THEME DESIGN Copyright © 2009 under GPL by Tribute Media. Site Powered by Drupal.